Cargando…

Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis

BACKGROUND: The study of cyclooxygenase-2 (COX-2) inhibitors is now mired in controversy. We performed a meta-analysis to assess the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: A literature search of PubMed, EMBA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Ping, Li, Jing, Ma, Xiao-Ping, Huang, Jian, Meng, Juan-Juan, Gong, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804138/ https://www.ncbi.nlm.nih.gov/pubmed/29440919 http://dx.doi.org/10.2147/OTT.S148670

Ejemplares similares

The Efficacy and Safety of Afatinib in Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Meta-Analysis
por: Jin, Hui, et al.
Publicado: (2023)

Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis
por: Xu, Yu-Qiong, et al.
Publicado: (2021)

Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2020)

Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer: A meta-analysis
por: Zhang, Pei-Pei, et al.
Publicado: (2021)

Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
por: Cai, Zijing, et al.
Publicado: (2022)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta‑analysis
por: Li, Zixiong, et al.
Publicado: (2023)

Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Hongman, et al.
Publicado: (2018)

Pharmacology, safety, efficacy and clinical uses of the COX‐2 inhibitor robenacoxib
por: Lees, Peter, et al.
Publicado: (2022)

Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer
por: Gu, Liyan, et al.
Publicado: (2019)

Efficacy and safety of bevacizumab combined with EGFR‐TKIs in advanced non‐small cell lung cancer: A meta‐analysis
por: Yang, Yifan, et al.
Publicado: (2021)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis
por: Fan, Xiao-Liang, et al.
Publicado: (2015)

Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Tian, Wei, et al.
Publicado: (2013)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Analgesic effects of the COX-2 inhibitor parecoxib on surgical pain through suppression of spinal ERK signaling
por: GUO, YA-JING, et al.
Publicado: (2013)

Clinical Efficacy and Safety of Cox-Maze IV Procedure for Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy
por: Meng, Yanhai, et al.
Publicado: (2021)

Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis
por: Cai, Qi, et al.
Publicado: (2022)

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
por: Dai, Jiali, et al.
Publicado: (2023)

Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review
por: Mathew, Sam T., et al.
Publicado: (2011)

Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study
por: Li, Xiao-Ping, et al.
Publicado: (2022)

Efficacy and safety of chemotherapy for newly diagnosed advanced non-small cell lung cancer with venous thromboembolism
por: Zhang, Xueli, et al.
Publicado: (2015)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis
por: Wu, Lin-guang-jin, et al.
Publicado: (2021)

Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
por: Wang, Liming, et al.
Publicado: (2021)

The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Peng, Ze, et al.
Publicado: (2021)

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis
por: Liu, Yi, et al.
Publicado: (2019)

Efficacy and safety of second‐line chemotherapy for patients with advanced non‐small cell lung cancer complicated by interstitial lung disease
por: Otsuka, Kenji, et al.
Publicado: (2022)

Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer
por: Pan, Cailong, et al.
Publicado: (2019)

Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer
por: Xie, Jiejie, et al.
Publicado: (2022)

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer
por: Lin, Heng, et al.
Publicado: (2016)

Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Guo, Wei-wei, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
por: Gao, Yuan, et al.
Publicado: (2015)

Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer
por: Hou, Xinlei, et al.
Publicado: (2022)

Clinical Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials
por: Yin, Qing, et al.
Publicado: (2022)

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Song, Ik-Chan, et al.
Publicado: (2015)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

Efficacy and Safety of Cinobufacin Combined with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis
por: Xu, Jing, et al.
Publicado: (2020)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
por: Wang, Hai-ying, et al.
Publicado: (2020)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Efficacy and safety of consolidation chemotherapy during the resting period in patients with local advanced rectal cancer
por: Liang, Huan-Qing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8dkcjihqm9uqbnbu1hsk1ei1nc